|
1.
|
Salomon JA, Vos T, Hogan DR, et al: Common
values in assessing health outcomes from disease and injury:
disability weights measurement study for the Global Burden of
Disease Study 2010. Lancet. 380:2129–2143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
3.
|
Kushi LH, Byers T, Doyle C, et al:
American Cancer Society Guidelines on Nutrition and Physical
Activity for cancer prevention: reducing the risk of cancer with
healthy food choices and physical activity. CA Cancer J Clin.
56:254–281; quiz 313–314. 2006. View Article : Google Scholar
|
|
4.
|
Lee JH, Miele ME, Hicks D, et al: KiSS-1,
a novel human malignant melanoma metastasis-suppressor gene. J Natl
Cancer Inst. 88:1731–1737. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Makri A, Pissimissis N, Lembessis P, et
al: The kisspeptin (KISS-1)/GPR54 system in cancer biology. Cancer
Treat Rev. 34:682–692. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Ohtaki T, Shintani Y, Honda S, et al:
Metastasis suppressor gene KiSS-1 encodes peptide ligand of a
G-protein-coupled receptor. Nature. 411:613–617. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Muir AI, Chamberlain L, Elshourbagy NA, et
al: AXOR12, a novel human G protein coupled receptor, activated by
the peptide KiSS-1. J Biol Chem. 276:28969–28975. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kotani M, Detheux M, Vandenbogaerde A, et
al: The metastasis suppressor gene KiSS-1 encodes kisspeptins, the
natural ligands of the orphan G protein-coupled receptor GPR54. J
Biol Chem. 276:34631–34636. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Nash KT and Welch DR: The KISS1 metastasis
suppressor: mechanistic insights and clinical utility. Front
Biosci. 11:647–659. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Cebrian V, Fierro M, Orenes-Piñero E, et
al: KISS1 methylation and expression as tumor stratification
biomarkers and clinical outcome prognosticators for bladder cancer
patients. Am J Pathol. 179:540–546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Moya P, Esteban S, Fernandez-Suarez A, et
al: KiSS-1 methylation and protein expression patterns contribute
to diagnostic and prognostic assessments in tissue specimens for
colorectal cancer. Tumour Biol. 34:471–479. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Cristofanilli M, Hayes DF, Budd GT, et al:
Circulating tumor cells: a novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Cristofanilli M, Budd GT, Ellis MJ, et al:
Circulating tumor cells, disease progression, and survival in
metastatic breast cancer. N Engl J Med. 351:781–791. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Osta WA, Chen Y, Mikhitarian K, et al:
EpCAM is overexpressed in breast cancer and is a potential target
for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Gusterson BA, Ross DT, Heath VJ, et al:
Basal cytokeratins and their relationship to the cellular origin
and functional classification of breast cancer. Breast Cancer Res.
7:143–148. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Allard WJ, Matera J, Miller MC, et al:
Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004.
View Article : Google Scholar
|
|
17.
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumor cells. Nat Rev Cancer. 8:329–340. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Masui T, Doi R, Mori T, et al: Metastin
and its variant forms suppress migration of pancreatic cancer
cells. Biochem Biophys Res Commun. 315:85–92. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Martin TA, Watkins G and Jiang WG: KiSS-1
expression in human breast cancer. Clin Exp Metastasis. 22:503–511.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Nicolle G, Comperat E, Nicolaïew N, et al:
Metastin (KISS-1) and metastin-coupled receptor (GPR54) expression
in transitional cell carcinoma of the bladder. Ann Oncol.
18:605–606. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Zohrabian VM, Nandu H, Gulati N, et al:
Gene expression profiling of metastatic brain cancer. Oncol Rep.
18:321–328. 2007.PubMed/NCBI
|
|
22.
|
Hata K, Dhar DK, Watanabe Y, et al:
Expression of metastin and a G-protein-coupled receptor (AXOR12) in
epithelial ovarian cancer. Eur J Cancer. 43:1452–1459. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Yamashita S, Tsujino Y, Moriguchi K, et
al: Chemical genomic screening for methylation-silenced genes in
gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment
and oligonucleotide microarray. Cancer Sci. 97:64–71.
2006.PubMed/NCBI
|
|
24.
|
Mooez S, Malik FA, Kayani MA, et al:
Expressional alterations and transcript isoforms of metastasis
suppressor genes (KAI1 and KiSS1) in breast cancer patients. Asian
Pac J Cancer Prev. 12:2785–2791. 2011.PubMed/NCBI
|
|
25.
|
Teng Y, Liu M and Cowell JK: Functional
interrelationship between the WASF3 and KISS1 metastasis-associated
genes in breast cancer cells. Int J Cancer. 129:2825–2835. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Dhar DK, Naora H, Kubota H, et al:
Downregulation of KiSS-1 expression is responsible for tumor
invasion and worse prognosis in gastric carcinoma. Int J Cancer.
111:868–872. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zheng S, Chang Y, Hodges KB, et al:
Expression of KISS1 and MMP-9 in non-small cell lung cancer and
their relations to metastasis and survival. Anticancer Res.
30:713–718. 2010.PubMed/NCBI
|
|
28.
|
Pantel K and Brakenhoff RH: Dissecting the
metastatic cascade. Nat Rev Cancer. 4:448–456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Müller V, Stahmann N, Riethdorf S, et al:
Circulating tumor cells in breast cancer: correlation to bone
marrow micrometastases, heterogeneous response to systemic therapy
and low proliferative activity. Clin Cancer Res. 11:3678–3685.
2005.
|
|
30.
|
Slade MJ, Payne R, Riethdorf S, et al:
Comparison of bone marrow, disseminated tumour cells and
bloodcirculating tumour cells in breast cancer patients after
primary treatment. Br J Cancer. 100:160–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lee YR, Tsunekawa K, Moon MJ, et al:
Molecular evolution of multiple forms of kisspeptins and GPR54
receptors in vertebrates. Endocrinology. 150:2837–2846. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Yan C, Wang H and Boyd DD: KISS-1
represses 92-kDa type IV collagenase expression by down-regulating
NF-kappa B binding to the promoter as a consequence of Ikappa
Balpha-induced block of p65/p50 nuclear translocation. J Biol Chem.
276:1164–1172. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Mandache E, Gherghiceanu M, Serafinceanu
C, et al: Myofibroblast involvement in tubular basement membrane
remodeling in type II diabetic nephropathy. Rom J Morphol Embryol.
52:75–79. 2011.PubMed/NCBI
|
|
34.
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Salomon DS, Brandt R and Ciardiello F:
Epidermal growth factor-related peptides and their receptors in
human malignancies. Crit Rev Oncol Hematol. 19:183–232. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Woessmann W, Chen X and Borkhardt A:
Ras-mediated activation of ERK by cisplatin induces cell death
independently of p53 in osteosarcoma and neuroblastoma cell lines.
Cancer Chemother Pharmacol. 50:397–404. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Bacus SS, Gudkov AV, Lowe M, et al:
Taxol-induced apoptosis depends on MAP kinase pathways (ERK and
p38) and is independent of p53. Oncogene. 20:147–155. 2001.
View Article : Google Scholar : PubMed/NCBI
|
